EV/EBITDA spoločnosti Kazia Therapeutics
Aká je hodnota metriky EV/EBITDA spoločnosti Kazia Therapeutics?
Hodnota metriky EV/EBITDA spoločnosti Kazia Therapeutics Limited je N/A
Aká je definícia metriky EV/EBITDA?
EV/EBITDA je podniková hodnota vydelená EBITDA (zisk pred odpočítaním úrokov, daní, odpisov, a amortizácie). Meria nákladnosť akcie a používa sa na porovnávanie spoločností medzi sebou častejšie ako P/E ratio. Meria cenu akú investor zaplatí za pohyb hotovosti v spoločnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA spoločností v sektore Health Care sektor na ASX v porovnaní so spoločnosťou Kazia Therapeutics
Čomu sa venuje spoločnosť Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Firmy s metrikou ev/ebitda podobnou spoločnosti Kazia Therapeutics
- Hodnota metriky EV/EBITDA spoločnosti NeonMind Biosciences je N/A
- Hodnota metriky EV/EBITDA spoločnosti Lumos Diagnostics je N/A
- Hodnota metriky EV/EBITDA spoločnosti Bluewater Acquisition Corp je N/A
- Hodnota metriky EV/EBITDA spoločnosti Guyana Goldstrike Inc je N/A
- Hodnota metriky EV/EBITDA spoločnosti BrewBilt Manufacturing je N/A
- Hodnota metriky EV/EBITDA spoločnosti Sable Resources je N/A
- Hodnota metriky EV/EBITDA spoločnosti Kazia Therapeutics je N/A
- Hodnota metriky EV/EBITDA spoločnosti engage:BDR je N/A
- Hodnota metriky EV/EBITDA spoločnosti Viaan Industries je N/A
- Hodnota metriky EV/EBITDA spoločnosti Antera Ventures Ii Corp je N/A
- Hodnota metriky EV/EBITDA spoločnosti MacDonald Mines Exploration je N/A
- Hodnota metriky EV/EBITDA spoločnosti Sihayo Gold je N/A
- Hodnota metriky EV/EBITDA spoločnosti Fabled Copper je N/A